Global Cardiology Academy

Welcome to Global
Cardiology Academy

Enhance your cardiology practice with CME and
tools focused on heart health management.

OCEAN Trial at AHA 2025: Anticoagulation After AF Ablation in High-Risk Patients
OCEAN Trial at AHA 2025: Anticoagulation After AF Ablation in High-Risk Patients
Cardiology
OCEAN Trial at AHA 2025: Anticoagulation After AF Ablation in High-Risk Patients
- Atul Verma, MD
POLY HF Trial: A Polypill Strategy for Heart Failure With Reduced Ejection Fraction (HFrEF)
POLY HF Trial: A Polypill Strategy for Heart Failure With Reduced Ejection Fraction (HFrEF)
Cardiology
POLY HF Trial: A Polypill Strategy for Heart Failure With Reduced Ejection Fraction (HFrEF)
- Ambarish Pandey, MD
ADAPT AF-DES: Antithrombotic Strategies Beyond 12 Months for Patients With AF Treated With Drug-Eluting-Stents
ADAPT AF-DES: Antithrombotic Strategies Beyond 12 Months for Patients With AF Treated With Drug-Eluting-Stents
Cardiology
ADAPT AF-DES: Antithrombotic Strategies Beyond 12 Months for Patients With AF Treated With Drug-Eluting-Stents
- Jung-Sun Kim, MD, PhD
Real-World Impact of Evolocumab on MACE Reduction in ASCVD
Real-World Impact of Evolocumab on MACE Reduction in ASCVD
Cardiology
Real-World Impact of Evolocumab on MACE Reduction in ASCVD
- Nihar Desai, MD
Global Burden of Stroke and Myocardial Infarction in Patients at High Risk of First MACE: Insights From the VESALIUS-REAL Study
Global Burden of Stroke and Myocardial Infarction in Patients at High Risk of First MACE: Insights From the VESALIUS-REAL Study
Cardiology
Global Burden of Stroke and Myocardial Infarction in Patients at High Risk of First MACE: Insights From the VESALIUS-REAL Study
- Matthew Jay Budoff, MD
Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
Nephrology
Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
- prof. Hiddo Heerspink
Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
Nephrology
Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
- Richard E. Pratley, MD
The Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
The Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
Nephrology
The Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
- Rajiv Agarwal, MBBS, MD, FASN, BRCU

Programs

The Fifth Pillar? Closing the Gap in HFrEF
The Fifth Pillar? Closing the Gap in HFrEF
CME/CE
The Fifth Pillar? Closing the Gap in HFrEF
0.50 credits
- Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC
- Javed Butler, MD
- Stephen J. Greene, MD, FACC, FHFSA
0.50 credits
Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
Cardiology
Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
- Ahmad Masri, MD, MS
DECAF Trial: Does Eliminating Coffee Reduce Atrial Fibrillation Recurrence in Symptomatic Patients?
DECAF Trial: Does Eliminating Coffee Reduce Atrial Fibrillation Recurrence in Symptomatic Patients?
Cardiology
DECAF Trial: Does Eliminating Coffee Reduce Atrial Fibrillation Recurrence in Symptomatic Patients?
- Christopher Wong
DARE AF Trial: Dapagliflozin to Reduce AF Burden After Catheter Ablation in Patients Without Diabetes or Heart Failure
DARE AF Trial: Dapagliflozin to Reduce AF Burden After Catheter Ablation in Patients Without Diabetes or Heart Failure
Cardiology
DARE AF Trial: Dapagliflozin to Reduce AF Burden After Catheter Ablation in Patients Without Diabetes or Heart Failure
- Clyde W. Yancy, MD
Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke: Primary Results of the VESALIUS-CV Trial 
Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke: Primary Results of the VESALIUS-CV Trial 
Cardiology
Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke: Primary Results of the VESALIUS-CV Trial 
- Lawrence Leiter
Case-Based Approach: Optimizing Cardio-Kidney-Metabolic Outcomes in Individuals With T2D & CKD
Case-Based Approach: Optimizing Cardio-Kidney-Metabolic Outcomes in Individuals With T2D & CKD
CME/CE
Case-Based Approach: Optimizing Cardio-Kidney-Metabolic Outcomes in Individuals With T2D & CKD
0.25 credits
- Rajiv Agarwal, MBBS, MD, FASN, BRCU
- Prof. Dr. Francesc Xavier Cos Claramunt
0.25 credits
MinuteCE®
Decoding Itch in CKD: From CKD-aP Suspicion to Solution
1.00 credit 9 episodes
- James Burton, DM, FRCP
- Leonie Kraft, MD
- Lucio Manenti, MD, PhD
- Emilio Sanchez, MD, PhD
1.00 credit 9 episodes
Optimizing Outcomes in Patients With oHCM: The Emerging Role of Cardiac Myosin Inhibitors
Optimizing Outcomes in Patients With oHCM: The Emerging Role of Cardiac Myosin Inhibitors
CME/CE Broadcast Replay
Optimizing Outcomes in Patients With oHCM: The Emerging Role of Cardiac Myosin Inhibitors
0.50 credits
- Iacopo Olivotto, MD
- Ahmad Masri, MD, MS
- Pablo Garcia-Pavia, MD, PhD
- Fabian Knebel, MD, PhD
- Caroline Coats, MD
0.50 credits

Clinical Practice

New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
Nephrology
New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
- prof. Hiddo Heerspink
PREVENT vs PCE: Refining ASCVD Risk Prediction in Statin-Treated Populations
PREVENT vs PCE: Refining ASCVD Risk Prediction in Statin-Treated Populations
Heart Matters
PREVENT vs PCE: Refining ASCVD Risk Prediction in Statin-Treated Populations
Sex-Based Differences in Lipid Management: Implications for Cardiovascular Risk
Sex-Based Differences in Lipid Management: Implications for Cardiovascular Risk
Heart Matters
Sex-Based Differences in Lipid Management: Implications for Cardiovascular Risk
Gender Bias and Heart Health: Improving Cardiovascular Care for Women
Gender Bias and Heart Health: Improving Cardiovascular Care for Women
Heart Matters
Gender Bias and Heart Health: Improving Cardiovascular Care for Women
Crossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
Crossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
CME/CE Broadcast Replay
Crossing Boundaries: CETP Inhibitors and the Next Frontier in Lipid Control
0.50 credits
- Prof. Ulrich Laufs
- Pam R. Taub, MD, FACC, FASPC
- Prof. John Kastelein, Chief Scientific Officer, NewAmsterdam Pharma
- Christie Ballantyne, MD
0.50 credits
Optimizing Outcomes: Evidence-Based Strategies for Treating Patients With Heart Failure With Mildly Reduced or Preserved Left Ventricular Ejection Fraction
Optimizing Outcomes: Evidence-Based Strategies for Treating Patients With Heart Failure With Mildly Reduced or Preserved Left Ventricular Ejection Fraction
CME/CE
Optimizing Outcomes: Evidence-Based Strategies for Treating Patients With Heart Failure With Mildly Reduced or Preserved Left Ventricular Ejection Fraction
0.25 credits
- John McMurray, MD
- Scott Solomon, MD
0.25 credits
VICTOR Prespecified Analysis Results: Vericiguat Effects on Mortality in Ambulatory Patients With HFrEF
VICTOR Prespecified Analysis Results: Vericiguat Effects on Mortality in Ambulatory Patients With HFrEF
Cardiology
VICTOR Prespecified Analysis Results: Vericiguat Effects on Mortality in Ambulatory Patients With HFrEF
- Stephen Greene
VICTOR Trial Results: Vericiguat Efficacy and Safety Across Baseline Background Therapy in Contemporary Ambulatory Patients With HFrEF
VICTOR Trial Results: Vericiguat Efficacy and Safety Across Baseline Background Therapy in Contemporary Ambulatory Patients With HFrEF
Cardiology
VICTOR Trial Results: Vericiguat Efficacy and Safety Across Baseline Background Therapy in Contemporary Ambulatory Patients With HFrEF
- Justin Ezekowitz, MD, MBBCh, MSc

CME

Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
CME/CE
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
- Kevin Alexander, MD
TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
CME/CE
TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
- Ahmad Masri, MD, MS
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
CME/CE
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
0.25 credits
- Riccardo Maria Inciardi, MD, PhD
0.25 credits
When and Why to Use CAC Scoring
When and Why to Use CAC Scoring
MinuteCE®
When and Why to Use CAC Scoring
1.00 program credit
- Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
- Rishi Wadhera, MD, MPP, Mphil
1.00 program credit
Statins and Safety: What the Data Say About Dementia, Cancer, and More
Statins and Safety: What the Data Say About Dementia, Cancer, and More
MinuteCE®
Statins and Safety: What the Data Say About Dementia, Cancer, and More
1.00 program credit
- Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
- Rishi Wadhera, MD, MPP, Mphil
1.00 program credit
Closing the Loop: Practical Strategies for Timely Lipid Panel Follow-Up
Closing the Loop: Practical Strategies for Timely Lipid Panel Follow-Up
MinuteCE®
Closing the Loop: Practical Strategies for Timely Lipid Panel Follow-Up
1.00 program credit
- Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
- Rishi Wadhera, MD, MPP, Mphil
1.00 program credit
MinuteCE®
From Risk to Results: Cases in ASCVD Prevention and Treatment
1.00 credit 10 episodes
- Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
- Rishi Wadhera, MD, MPP, Mphil
1.00 credit 10 episodes
Expanding Access: Alternative Models for Delivering Lipid-Lowering Therapy
Expanding Access: Alternative Models for Delivering Lipid-Lowering Therapy
MinuteCE®
Expanding Access: Alternative Models for Delivering Lipid-Lowering Therapy
1.00 program credit
- Rishi Wadhera, MD, MPP, Mphil
- Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
1.00 program credit